This Cutting Edge report examines market access staffing trends for four sub-groups based on surveyed market access teams across the US, European (EU) and Emerging Markets (EM):
Here are some key takeaways:
However, it is unclear the sizes of the firms included in the Cutting Edge survey and if the report has taken into account Outcomes FTEs housed outside Market Access such as those reside within Medical Affairs or standalone.
Based on bizi’s proprietary SME resourcing database for market access, among firms the database regularly tracks, in the US, Outcomes-Based FTEs vary significantly by company size and even among companies of similar size. Inclusive of field Outcomes personnel, large biopharma firms (1001+ employees) collectively employ more than 70% of the Outcomes FTEs. And only about 9% of late phase small biopharma firms (less than 500 employees) have dedicated in house Outcomes infrastructure. Device and diagnostics firms except for a few exceptions are lagging on HEOR infrastructure investment comparing to their biopharma counterparts.
- Outcomes-Based (HEOR, PRO, CER)
- Strategy-Focused (pricing and reimbursement)
- Relationship-Focused (account management, government affairs and launch sequencing) and
- General Market Access (anything not included in prior 3 sub-groups)
Here are some key takeaways:
- Relationship-focused personnel make up the largest percentage of the market access team globally while strategy-focused personnel make up the smallest percentage.
- Allocation of relationship-focused personnel dedicated to Government Affairs and Launch sequencing has increased considerably in the US from 1% in 2013 to 8% in 2015. Emerging Markets have the highest percentage of government affairs and launch sequencing FTEs, at 12% in 2015.
- Percentage of Market Access staffing dedicated to pricing has more than doubled to an average of 15% from 2013 to 2015 in EU and EM. US is the only surveyed region decreased pricing FTEs from 7% to 6% during the same period.
- Outcomes-Based staffing has increased from 1% (2013) to 6% (2015) among surveyed US Market Access teams. Yet US remains the lowest in FTE percentage for Outcomes-Based staffing comparing to EU (12%) and EM (15%).
However, it is unclear the sizes of the firms included in the Cutting Edge survey and if the report has taken into account Outcomes FTEs housed outside Market Access such as those reside within Medical Affairs or standalone.
Based on bizi’s proprietary SME resourcing database for market access, among firms the database regularly tracks, in the US, Outcomes-Based FTEs vary significantly by company size and even among companies of similar size. Inclusive of field Outcomes personnel, large biopharma firms (1001+ employees) collectively employ more than 70% of the Outcomes FTEs. And only about 9% of late phase small biopharma firms (less than 500 employees) have dedicated in house Outcomes infrastructure. Device and diagnostics firms except for a few exceptions are lagging on HEOR infrastructure investment comparing to their biopharma counterparts.
RSS Feed